No abstract

No abstract

No abstract

were shorter in gBRCA2 carriers who also present somatic BRCA2-RB1 codel or MYC amplification compared with gBRCA2 without such alterations. SImilar results were observed in NC (Table ). MVA model confirmed the independent prognostic value of somatic BRCA2-RB1 codel (HR 4.13; p¼0.004) and MYC amplif (HR 2.27; p¼0.033) for CSS.Conclusions: PROREPAIR-A is the largest series of gBRCA2 tumors assembled to date to explore associations between somatic alterations and clinical outcomes in PC. Our results suggest that somatic BRCA2-RB1 codel and MYC amplification define an aggressive subtype of PC with poor clinical outcomes in both gBRCA2 and NC.